Selected Publications

Academic Article

Year Title Altmetric
2019 Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing 2019
2019 The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population 2019
2019 Variation in use of procurement biopsies and its implications for discard of deceased donor kidneys recovered for transplantation 2019
2019 Time for reform in transplant program–specific reporting: AST/ASTS transplant metrics taskforce 2019
2019 Long-term follow-up of the DeKAF cross-sectional cohort study 2019
2019 Chronic dialysis in patients with end-stage renal disease: Relevance to kidney xenotransplantation 2019
2019 Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor—A multicenter analysis 2019
2019 Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups 2019
2018 Population Health, Ethnicity, and Rate of Living Donor Kidney Transplantation 2018
2018 Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors 2018
2018 Expanding clarity or confusion? Volatility of the 5-tier ratings assessing quality of transplant centers in the United States 2018
2018 Late graft failure after kidney transplantation as the consequence of late versus early events 2018
2018 Xenotransplantation - The current status and prospects 2018
2017 Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index 2017
2017 Obesity increases the risk of end-stage renal disease among living kidney donors 2017
2017 Access to kidney transplantation among HIV-infected waitlist candidates 2017
2017 Cost-effectiveness of antibody-based induction therapy in deceased donor kidney transplantation in the United States 2017
2016 APOL1 genotype and kidney transplantation outcomes from deceased african American donors 2016
2015 Moving beyond minimization trials in kidney transplantation 2015
2015 Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation 2015
2015 Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure 2015
2015 Identification of strategies to facilitate organ donation among african americans using the nominal group technique 2015
2015 Medical management of chronic kidney disease in the renal transplant recipient 2015
2015 Reassessing medical risk in living kidney donors 2015
2015 Through a glass darkly: Seeking clarity in preventing late kidney transplant failure 2015
2014 Kidneys at higher risk of discard: Expanding the role of dual kidney transplantation 2014
2014 Kidney donors at increased risk? Additional studies are needed 2014
2014 The high cost of organ transplant commercialism 2014
2013 Future of medicare immunosuppressive drug coverage for kidney transplant recipients in the United States 2013
2012 Erratum: A realistic proposal-incentives may increase donation - We need trials now! (American Journal of Transplantation (2012) 12 (1957-1958) DOI:10.1111/j.1600-6143.2012.04117.x) 2012
2012 Report of a consensus conference on transplant program quality and surveillance 2012
2012 The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival 2012
2012 Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients 2012
2012 Counseling patients for kidney transplantation: Awkward conversations? 2012
2012 A realistic proposal - Incentives may increase donation - We need trials now! 2012
2011 Our evolving understanding of late kidney allograft failure 2011
2011 The PROMISE study: A phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de Novo kidney transplantation 2011
2011 Therapeutic drug monitoring of mycophenolates in kidney transplantation: Report of The Transplantation Society consensus meeting 2011
2011 Advances in kidney transplant immunosuppression: Emerging biologics 2011
2011 Prevention of cardiovascular disease in adult recipients of kidney transplants 2011
2010 Living donor nephrectomy: Understanding long-term risk in minority populations 2010
2010 Optimal cutoff point for immunoperoxidase detection of C4d in the renal allograft: Results from a multicenter study 2010
2010 Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure 2010
2010 Evidence for antibody-mediated injury as a Major determinant of late kidney allograft failure 2010
2010 Optimizing medication adherence: An ongoing opportunity to improve outcomes after kidney transplantation 2010
2010 Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: Preliminary data from the DeKAF study 2010
2010 Pathological and clinical characterization of the 'Troubled transplant': Data from the DeKAF study 2010
2010 Mycophenolic acid exposure in high-and low-weight renal transplant patients after dosing with mycophenolate mofetil in the opticept trial 2010
2009 Chronic calcineurin inhibitor nephrotoxicity: Reflections on an evolving paradigm 2009
2009 Barriers to preemptive kidney transplantation 2009
2009 Use of cardioprotective medications in kidney transplant recipients 2009
2009 Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: The opticept trial 2009
2009 Transplant tourism and unregulated black-market trafficking of organs 2009
2009 A Festschrift honoring Dr. John J. Curtis. 2009
2009 Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant. 2009
2009 Must health literacy be a prerequisite for kidney transplantation? 2009
2008 Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: Preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics 2008
2008 Transplant tourism: A modern iteration of an ancient problem 2008
2008 Systolic dysfunction portends increased mortality among those waiting for renal transplant 2008
2008 Kidney transplantation as primary therapy for end-stage renal disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) conference 2008
2007 The impact of left ventricular systolic dysfunction on survival after renal transplantation 2007
2007 Role of β3 integrin in acute renal allograft rejection in humans 2007
2007 Must all living donor compensation be viewed as valuable consideration? [2] 2007
2007 Racial Disparities in Renal Allograft Survival: A Public Health Issue? 2007
2006 Limiting financial disincentives in live organ donation: A rational solution to the kidney shortage 2006
2006 The conspicuous costs of more of the same 2006
2006 Current and evolving immunosuppressive regimens in kidney transplantation 2006
2005 The relationship between ethnicity and outcomes in solid organ transplantation 2005
2005 Understanding the influence of ethnicity on renal allograft survival 2005
2005 Mycophenolate mofetil: Ten years of clinical experience. Introduction 2005
2005 Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts 2005
2005 Kidneys from deceased donors: Maximizing the value of a scarce resource 2005
2005 Long-term deterioration of kidney allograft function 2005
2005 Improving access to renal transplantation 2005
2004 "High-risk" renal transplantation: evolving definitions at a single center. 2004
2004 Transplantation in the diabetic patient with advanced chronic kidney disease: A task force report 2004
2004 Whither Living Donors? 2004
2003 Equivalent Pharmacokinetics of Mycophenolate Mofetil in African-American and Caucasian Male and Female Stable Renal Allograft Recipients 2003
2003 Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporin and steroids in renal transplantation 2003
2003 Determinants of cardiovascular mortality after renal transplantation: A role for cytomegalovirus? 2003
2003 Diabetes mellitus after kidney transplantation 2003
2003 The report of a national conference on the wait list for kidney transplantation 2003
2002 The nondirected live-kidney donor: Ethical considerations and practice guidelines. A national conference report 2002
2002 Addressing minority issues in renal transplantation: Is more equitable access an achievable goal? 2002
2002 African Americans and renal transplantation: Disproportionate need, limited access, and impaired outcomes 2002
2001 Noncomplication in solid organ transplantation 2001
2001 Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up 2001
2001 Evolution of immunosuppression and continued importance of acute rejection in renal transplantation 2001
2001 Maintenance immunosuppression in the renal transplant recipient: An overview 2001
2000 Renal transplantation in black Americans 2000
2000 Recommendations for the outpatient surveillance of renal transplant recipients 2000
2000 Prediction of renal transplant survival from early postoperative radioisotope studies 2000
2000 Posttransplant lymphoproliferative disorder localized near the allograft in renal transplantation 2000
2000 Erratum: Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens (Transplantation Proceedings Vol. 31 (Suppl. 8A) (1999) (17S-22S)) 2000
1999 Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection 1999
1999 Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens 1999
1998 Development and clinical utility of daclizumab (Zenapax®), a humanized anti-Tac monoclonal antibody, in renal transplantation 1998
1998 Stumbling toward equity: The role of government in kidney transplantation 1998
1998 Stumbling toward equity: the role of government in kidney transplantation. 1998
1998 Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation 1998
1998 Losartan, an Angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis 1998
1998 Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation 1998
1996 The evaluation of living renal transplant donors: Clinical practice guidelines 1996
1996 Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3 - A randomized, double-blind placebo-controlled study 1996
1996 Impact of donor/recipient size matching on outcomes in renal transplantation 1996
1996 Benefits of continued cyclosporine through an indigent drug program 1996
1996 Dilemmas in renal transplantation: When the clinical course and histological findings differ 1996
1996 Factors affecting renal allograft survival in african americans? 1996
1995 Evaluation of living renal donors: The current practice of US transplant centers 1995
1995 HLA matching in renal transplantation 1995
1995 Cyclosporine inhibits the renal response to L-arginine in human kidney transplant recipients 1995
1995 Progress in Renal Transplantation a Single Center Study of 3359 Patients over 25 Years 1995
1995 The evaluation of renal transplant candidates: Clinical practice guidelines 1995
1994 Delayed graft function after renal transplantation: Causes, implications, and clinical management 1994
1994 In Reply 1994
1994 Race and Allocation of Kidneys for Transplantation 1994
1994 Cytokines and transplantation: a clinical perspective. 1994
1994 Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis 1994
1994 Posttransplant Erythrocytosis: An Enigma Revisited 1994
1994 Renal retransplantation: The role of race, quadruple immunosuppression, and the flow cytometry cross-match 1994
1993 Racial Equity in Renal Transplantation: The Disparate Impact of HLA-Based Allocation 1993
1993 Unequal racial access to kidney transplantation. 1993
1993 Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients 1993
1993 Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center 1993
1993 Tapering or Discontinuing Cyclosporine for Financial Reasons—A Single-Center Experience 1993
1992 Benefits of quadruple immunosuppressive therapy in recipients of living related donor kidneys: A review of 855 operations 1992
1992 Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression 1992
1992 The impact of the UNOS mandatory sharing policy on recipients of the black and white races-experience at a single renal transplant center 1992
1991 Immunosuppression tailored to race 1991
1991 Analysis of 22 years experience in living-related transplantation at the University of Alabama in Birmingham. 1991
1991 Effects of enalapril on erythrocytosis after renal transplantation 1991
1991 OKT3 first-dose reaction: Association with T cell subsets and cytokine release 1991
1990 Donor antigen-specific immunosuppression in cadaveric and living-related donor kidney allograft recipients. 1990


Year Title Altmetric
2013 Mycophenolates.  250-266. 2013
2011 Immunosuppression: Past, present, and future.  19-30. 2011
2008 Hypertension in Renal Transplant Recipients.  675-679. 2008

Full Name

  • Robert Gaston